Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia

Overview

This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired bacterial pneumonia (HAP) or community-acquired bacterial pneumonia (CAP) requiring hospitalization, and requiring intravenous (IV) antibiotic therapy.

Full Title of Study: “A Multicentre, Randomized, Investigator-blind, Active-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ceftobiprole Versus Intravenous Standard-of-care Cephalosporin Treatment With or Without Vancomycin in Pediatric Patients Aged From 3 Months to Less Than 18 Years With Hospital-acquired Pneumonia or Community-acquired Pneumonia Requiring Hospitalisation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: March 16, 2020

Detailed Description

This was a randomized, investigator-blind, active-controlled multi-center study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ceftobiprole medocaril compared with IV standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients aged 3 months to less than 18 years with HAP or CAP requiring hospitalization and therapy with IV antibiotics. Randomization was stratified by four age groups (3 months to < 2 years; 2 years to < 6 years; 6 years to < 12 years; 12 years to < 18 years), and by diagnosis of HAP or CAP.

Interventions

  • Drug: ceftobiprole medocaril
    • Ceftobiprole medocaril was administered at age-adjusted doses (10, 15 or 20 mg/kg) and infusion durations (2 or 4 hours) every 8 hours. The maximum dose, regardless of body weight, was 500 mg ceftobiprole every 8 hours (maximum total daily dose of 1500 mg ceftobiprole). After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days’ antibiotic treatment.
  • Drug: IV standard-of-care cephalosporin
    • Ceftriaxone was administered at 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day. The actual dose of ceftriaxone within this dose range was determined by the blinded investigator prior to first study drug administration and was not modified during subsequent study days. After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days’ antibiotic treatment. At the discretion of the blinded investigator, patients received vancomycin at a dose of 10 to 15 mg/kg IV every 6 hours, up to a maximum dose of 2 g/day, in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed.

Arms, Groups and Cohorts

  • Experimental: Ceftobiprole medocaril
    • Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for IV administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
  • Active Comparator: IV standard-of-care cephalosporin
    • Ceftriaxone was used as standard-of-care cephalosporin for the treatment of CAP. It is a third-generation cephalosporin with activity against typical bacterial pathogens of CAP requiring hospitalization, and is widely used for the treatment of various bacterial infections in neonates, infants, children, and adults. Ceftazidime was used as standard-of-care cephalosporin for the treatment of HAP. It is also a third-generation cephalosporin, but with broader activity against Gram-negative aerobic bacilli, including Pseudomonas aeruginosa. Vancomycin is a glycopeptide antibiotic that is active against staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). At the discretion of the blinded investigator, patients received vancomycin in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed.

Clinical Trial Outcome Measures

Primary Measures

  • Adverse Events
    • Time Frame: Analysis of AEs assessed during the first 3 days of IV therapy and while on IV, a median of 7 days
    • Reported are adverse events (AEs) during the first 3 days of IV therapy and while patients were on IV therapy irrespective of when they switched to oral antibiotic treatment.

Secondary Measures

  • Proportion of Patients With Clinical Cure in the Intent-to-treat Population (ITT)
    • Time Frame: At the test-of-cure (TOC) visit
    • Comparison of clinical cure rates (signs and symptoms of pneumonia normalized or improved such that no further antibiotic therapy was necessary, and stabilization or improvement of chest X-ray findings if these were available) in the ITT population between ceftobiprole and the comparator at the TOC visit.
  • Proportion of Patients With Clinical Cure in the Clinically Evaluable (CE) Population
    • Time Frame: At the TOC visit
    • Comparison of clinical cure rates (signs and symptoms of pneumonia normalized or improved such that no further antibiotic therapy was necessary, and stabilization or improvement of chest X-ray findings if these were available) in the CE population between ceftobiprole and the comparator at the TOC visit.
  • Proportion of Patients With Early Clinical Response in the Intent-to-treat (ITT) Population
    • Time Frame: At Day 4
    • Comparison of early clinical response rates in the ITT population between ceftobiprole and the comparator at Day 4.
  • Proportion of Patients With Early Clinical Response in the Clinically Evaluable (CE) Population
    • Time Frame: At Day 4
    • Comparison of early clinical response rates in the CE population between ceftobiprole and the comparator at Day 4.

Participating in This Clinical Trial

Inclusion Criteria

  • Male of female aged 3 months to < 18 years with a body weight of at least 5 kg – Diagnosis of either hospital-acquired pneumonia or community-acquired pneumonia requiring hospitalization and administration of IV antibiotic therapy – New or progressive imaging findings consistent with bacterial pneumonia – Requirement for IV antibacterial treatment for pneumonia – Other inclusion criteria may apply Exclusion Criteria:

  • Known resistance of the causative pathogen to ceftobiprole or IV standard-of-care cephalosporin treatment (± vancomycin) – On mechanical ventilation – Chest trauma with severe lung contusion or flail chest – Acute respiratory distress syndrome – Empyema or lung abscess – Anatomical bronchial obstruction – Active or currently treated pulmonary tuberculosis – Atypical bacterial pneumonia, or viral pneumonia without bacterial superinfection, or need for antibiotic coverage with a macrolide – Pertussis, chemical pneumonitis, or cystic fibrosis – Severe immunodeficiency – Significant laboratory abnormalities including: Hematocrit <20%; absolute neutrophil count <0.5×10⁹/L; platelet count <50×10⁹/L; alanine aminotransferase, aspartate aminotransferase, or bilirubin >5 times the age-specific upper limit of normal; – Creatinine clearance <50 mL/min/1.73 m² – Use of systemic antimicrobial therapy for more than 24 hours in the 48 hours before randomization – History of a previous clinically-relevant hypersensitivity or serious adverse reaction to beta lactam antibiotics or to vancomycin – Poorly controlled seizure disorder – Other exclusion criteria may apply

Gender Eligibility: All

Minimum Age: 3 Months

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Basilea Pharmaceutica
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marc Engelhardt, MD, Study Director, Basilea Pharmaceutica

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.